Please assess the completion status of the following clinical trial:

Trial Title: Study of Eteplirsen in Young Participants With Duchenne Muscular Dystrophy (DMD) Amenable to Exon 51 Skipping

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male between 6 months to 48 months of age (inclusive)~* Diagnosis of DMD with a deletion mutation amenable to exon 51 skipping~* Parent(s) or legal guardian(s) who is willing to provide written informed consent~Exclusion Criteria:~* Received treatment that might have an effect on muscle strength or function within 12 weeks prior to dosing~* Received previous or current treatment with any experimental treatment~* Clinically significant illness other than DMD~* Clinically significant laboratory abnormality~* Any other condition that could interfere with the participation in the study.

- Gender: MALE
- Minimum Age: 6 Months
- Maximum Age: 48 Months
- Healthy Volunteers: f

Study Arms:
- Eteplirsen (Type: EXPERIMENTAL): Eteplirsen will be administered once every 7 days by intravenous (IV) infusion starting on Day 1 for up to 96 weeks. The starting dose will be 2 milligrams/kilogram (mg/kg) eteplirsen, with escalation to 4, 10, 20, and 30 mg/kg for 10 weeks, and then participants will continue to receive eteplirsen at 30 mg/kg for the duration of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).